8-K: Biohaven's Troriluzole Shows Positive Results in Pivotal Spinocerebellar Ataxia Study

Biohaven's troriluzole demonstrated significant efficacy in slowing the progression of Spinocerebellar Ataxia (SCA) in a pivotal study, paving the way for a potential new treatment.

Summary

• Biohaven announced positive topline results from a pivotal study of troriluzole in patients with Spinocerebellar Ataxia (SCA).
• The study, BHV4157-206-RWE, met its primary endpoint, showing statistically significant improvements in the modified functional Scale for the Assessment and Rating of Ataxia (f-SARA) after 3 years of treatment.
• Troriluzole also demonstrated statistically significant improvements at years 1 and 2.
• The treatment showed a 50-70% slowing of disease progression compared to untreated patients, representing a 1.5-2.2 year delay in disease progression over the 3-year study period.
• The study included 63 subjects completing 3 years of treatment with troriluzole, matched to an external control arm.
• The study used both a US-based and a European-based external control group for comparison, with consistent results across both groups.
• Biohaven plans to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2024.
• The company is preparing for potential commercialization in the US in 2025, pending FDA approval.

Sentiment

Score: 9

Explanation: The document presents highly positive results from a pivotal study, with clear statistical significance and a clinically meaningful impact. The planned NDA submission and potential commercialization timeline further boost the positive sentiment.

Positives

• The study achieved its primary endpoint, demonstrating the efficacy of troriluzole in slowing SCA progression.
• Troriluzole showed statistically significant improvements at years 1, 2, and 3 of treatment.
• The treatment resulted in a clinically meaningful slowing of disease progression, with a 50-70% reduction in the rate of decline.
• The study used rigorous matching of treated and untreated patients, enhancing the reliability of the results.
• The use of both US and European control groups strengthens the global applicability of the findings.
• The company has received Fast-Track and Orphan Drug designations, which could expedite the FDA review process.
• Biohaven is preparing for commercialization in the US in 2025, indicating a clear path to market if approved.

Risks

• The NDA submission to the FDA is planned for Q4 2024, and there is no guarantee of approval.
• Commercialization in 2025 is contingent on FDA approval and priority review timelines.
• The study relied on external control groups, which may introduce some limitations compared to a traditional placebo-controlled trial.
• The forward-looking statements are subject to various risks and uncertainties, including clinical trial outcomes and regulatory approvals.

Future Outlook

Biohaven plans to submit an NDA to the FDA in Q4 2024 and is preparing for potential commercialization in the US in 2025, pending FDA approval. The company is also exploring the potential of troriluzole in other diseases associated with excessive glutamate.

Management Comments

• Dr. Susan Perlman stated that troriluzole is the first treatment to show a delay in disease progression, offering patients additional years of independence.
• Jeremy Schmahmann, M.D., commented on the therapeutic potential of troriluzole and its impact on patients and caregivers.
• Vlad Coric, M.D., highlighted the company's commitment to developing novel therapies for rare diseases and the collaboration with various partners.
• Andrew Rosen shared that Biohaven was the first company to join NAF's Drug Development Collaborative.

Industry Context

This announcement is significant as there are currently no FDA-approved treatments for SCA, a rare and debilitating neurodegenerative disease. The positive results for troriluzole position Biohaven as a potential leader in this therapeutic area, addressing a significant unmet medical need.

Comparison to Industry Standards

• The study utilized a real-world evidence approach, which is becoming more common in rare disease research, but is not as robust as a traditional placebo controlled trial.
• The use of external control groups from both the US and Europe provides a more comprehensive view of the treatment's efficacy.
• The 50-70% slowing of disease progression is a significant outcome compared to the natural progression of SCA, where patients typically experience a steady decline.
• The study's results are particularly noteworthy given the lack of existing FDA-approved treatments for SCA, setting a new benchmark for potential therapies.

Stakeholder Impact

• Shareholders are likely to react positively to the news of successful clinical trial results and the potential for a new product launch.
• Patients with SCA and their families will benefit from the potential availability of a treatment that can slow disease progression.
• The medical community will gain a new tool for managing SCA, a disease with no current FDA-approved treatments.
• Employees of Biohaven may experience increased job security and opportunities due to the company's progress.

Next Steps

• Biohaven plans to submit a New Drug Application (NDA) to the FDA in the fourth quarter of 2024.
• The company will interact with regulatory agencies to bring troriluzole to patients with SCA.
• Biohaven is preparing for potential commercialization in the US in 2025, pending FDA approval.

Key Dates

Keywords

Troriluzole, Spinocerebellar Ataxia, SCA, Neurodegenerative Disease, FDA, NDA, Clinical Trial, Orphan Drug Designation, Real-World Evidence, f-SARA